Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer
NL-OMON60682Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine-releasing intravesical system, cetrelimab and gemcitabine in transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall complete response rate and Disease-free survival. Started Nov 2025; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimabgemcitabine
03
Conditions
transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on NL-OMON60682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60682.